miR-21-5p targets SKP2 to reduce osteoclastogenesis in a mouse model of osteoporosis

Yizhen Huang,Yute Yang,Jianle Wang,Shasha Yao,Teng Yao,Yining Xu,Zizheng Chen,Putao Yuan,Jun Gao,Shuying Shen,Jianjun Ma
DOI: https://doi.org/10.1016/j.jbc.2021.100617
IF: 5.485
2021-01-01
Journal of Biological Chemistry
Abstract:Osteoporosis results from an imbalance between bone formation and bone resorption. Traditional drugs for treating osteoporosis are associated with serious side effects, and thus, new treatment methods are required. This study investigated the role of differentially expressed microRNAs during osteoclast differentiation and osteoclast activity during osteoarthritis as well as the associated underlying mechanisms. We used a microarray to screen microRNAs that decreased in the process of osteoclast differentiation and verified miR-21-5p to decrease significantly using RT-qPCR. In follow-up experiments, we found that miR-21-5p targets SKP2 to regulate osteoclast differentiation. In vivo, ovariectomized mice were used to simulate perimenopausal osteoporosis induced by estrogen deficiency, and miR-21-5p treatment inhibited bone resorption and maintained bone cortex and trabecular structure. These results suggest that miR-21-5p is a new therapeutic target for osteoporosis.
biochemistry & molecular biology
What problem does this paper attempt to address?